HEMOGLOBIN-BASED OXYGEN CARRIERS: MECHANISMS OF TOXICITY NIH GUIDE, Volume 21, Number 42, November 20, 1992 PA: PA-93-23 P.T. 34 Keywords: Hematology Biochemistry Biology, Cellular Biology, Molecular Pharmacology Pathophysiology National Heart, Lung, and Blood Institute PURPOSE The National Heart, Lung, and Blood Institute (NHLBI) announces a Program Announcement (PA) on the above subject. The purpose of this initiative is to encourage research aimed at providing an understanding of the mechanisms of toxicity of hemoglobin-based oxygen carriers. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Hemoglobin-based Oxygen Carriers: Mechanisms of Toxicity, is related to the priority area of food and drug safety. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-782-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal Government. Applications from minority individuals and women are encouraged. Awards in connection with this announcement will be made to foreign institutions only for research of very unusual merit, need and promise, and in accordance with PHS policy governing such awards. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. MECHANISM OF SUPPORT This PA will use the National Institutes of Health (NIH) research project grant (R01) and FIRST (R29) award. Applicants, who will plan and execute their own research programs, are requested to furnish their own estimates of the time required to achieve the objectives of the proposed research project. Up to five years of support may be requested. Because the nature and scope of the research proposed in response to this PA may vary, it is anticipated that the size of an award will also vary. Those applicants requesting support under the FIRST (R29) award should be certain that the direct costs requested are within the guidelines for that award. Administrative adjustments in project period and/or amount of support may be required at the time of the award. All current policies and requirements that govern the research grant programs of the NIH will apply to grants awarded in connection with this PA. RESEARCH OBJECTIVES Background An alternative to red blood cells for transfusion has been sought unsuccessfully for over one hundred years. In recent years, the NHLBI and other government agencies have supported research on the development of stable oxygen carriers that do not need to be cross-matched and that can be stored for extended periods of time. During the past decade, awareness of the dangers inherent in transfusion of homologous red blood cells has heightened. These include transmission of infectious agents such as HIV, hepatitis viruses and other microorganisms. Consequently, physicians are increasingly reluctant to transfuse their patients and patients are increasingly reluctant to receive blood. Although testing of units of blood is becoming more comprehensive and efficient, there is no question that products that are free of infectious agents that could be used in place of red cells would have wide clinical application. In spite of this promise, studies of hemoglobin-based oxygen carriers have been disappointing as unpredictable toxicities have thwarted development of clinically useful products. Infusion of hemoglobin-based oxygen carriers into the circulation can result in a variety of outcomes. Carrier molecules may leave the circulation by a number of routes including endothelial transcytosis, phagocytic uptake, and diffusion. The effects of these materials may be as diverse as the range of properties of the various tissues they bathe. Their interaction with endothelium-derived relaxing factors, stimulation of other vasoactive materials, and stimulation of mediators of inflammation may add to the complex biological reactions noted in research to date. Furthermore, much of the previous work in this field is clouded by species differences, so that, at present, there are no animal or in vitro models that will reliably predict human reactions. In addition to Federal support, research and development of artificial oxygen carriers have been carried out by industry. Indeed, industry has contributed valuable knowledge in the area of product and quality control. Sophisticated high technology systems have been developed to produce products in large quantities. However, in recent clinical trials with hemoglobin-based oxygen carriers, unexpected toxicities were observed suggesting the need for more basic research to address fundamental questions concerning interaction with the immune system and endothelium in particular. Research Objectives and Experimental Approaches The purpose of this PA is to encourage research aimed at providing an understanding of the mechanisms of toxicity of hemoglobin-based oxygen carriers. This program encourages research addressing such fundamental questions as: (1) what are the mechanisms of vasoactivity of hemoglobin solutions, (2) how do protein modifications affect vasoactivity, (3) what are the mechanisms of stimulation of inflammation mediators by hemoglobin-based oxygen carriers, (4) how can this stimulation be prevented, (5) what animal or in vitro models are best used to study toxic effects of oxygen carriers, (6) what are the long-term (metabolic and pharmacologic) effects of oxygen carriers, and (7) what models are best to demonstrate efficacy in terms of oxygen transport to tissue. Particular encouragement is offered to investigators possessing modern tools, who are well-trained, and who are currently pursuing other research interests to devote time and resources to this area. It is hoped that interdisciplinary and collaborative approaches may be developed which will complement the efforts of workers in the field. The ultimate goal is to satisfy a fundamental need in clinical medicine, i.e., development of a safe, economical and efficacious alternative to homologous human red blood cells for transfusion. Examples of promising topics are: o Studies of the interaction of hemoglobin with endothelium and macrophages. o Development of animal models that simulate clinical use, such as trauma, shock, infection, and surgical blood loss. o Studies relating the biochemical modification of hemoglobin with its biological effects. o Studies of encapsulation of hemoglobin into artificial vesicles - biochemical, physical, physiological, and biological effects. o Studies of the tissue distribution and metabolic fate of modified hemoglobins, and artificial vesicles. These are intended as examples only. Investigators are encouraged to consider other innovative approaches. Applications may address one or several issues, but should retain a common theme and focus on addressing those issues. Because issues involving hematology, biochemistry, physiology, cell biology, pharmacology or molecular biology may need to be addressed in a coordinated manner, collaboration among investigators having expertise in these and other appropriate disciplines is encouraged. When individuals are at different institutions, individual R01 applications may include consortium arrangements. While the main focus of this PA is on basic or fundamental research studies to elucidate the mechanisms of toxicity of hemoglobin-based oxygen carriers, clinical studies, but not clinical trials, are also appropriate. Collaborative arrangements with ongoing clinical studies or trials that provide patient material at little or no cost to the applicant are also encouraged. Such arrangements should be clearly delineated in the application. The description should include sufficient information to permit scientific evaluation of the studies proposed. Among issues to include are the number and type of specimens/patients, patient population characteristics (including gender and minority composition; see STUDY POPULATIONS below), overall goals of the collaborative project, remaining term of the project, and IRB approval of the project. If substantial interactions and costs with ongoing projects are proposed, a consortium agreement can be developed and submitted to support this additional research aspect. If statistical analysis is anticipated, the methodologies and personnel involved should be described in the application and evident in the study design. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans including American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, and Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be deferred until the information is provided. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 9/91) and will be accepted at the standard application deadlines as indicated in the application kit. The receipt dates for applications for AIDS-related research are found in the PHS 398 (rev. 9/91) instructions. FIRST award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7441. Section 2 on the face page of the application must be completed. Check "YES" to indicate the application is submitted in response to a program announcement. The title and program announcement number must be typed in Section 2a of the application as follows: "HEMOGLOBIN-BASED OXYGEN CARRIERS: MECHANISMS OF TOXICITY" PA-93-23. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW CONSIDERATIONS Although this is an NHLBI PA, the National Institute of Environmental Health Sciences also has an interest in the subject matter of this PA. Applications will be assigned to the most appropriate Institute on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard peer review procedures. Following scientific-technical review, the applications will receive a second-level review by the appropriate advisory council. AWARD CRITERIA Funding decisions will be made on the basis of scientific and technical merit of the proposed grant as determined by peer review, program needs, balance among research areas of the announcement, and the availability of funds. Awards in response to this PA will be made to foreign institutions only for research of very unusual merit, need, and promise, and in accordance with PHS policy governing such awards. INQUIRIES Inquiries regarding this program announcement may be directed to: Dr. George J. Nemo Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute Federal Building, Room 504 Bethesda, MD 20892 Telephone: (301) 496-1537 FAX: (301) 496-9940 For fiscal and administrative matters, contact: Ms. Jane R. Davis Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 4A15 Bethesda, MD 20892 Telephone: (301) 496-7257 FAX: (301) 402-1200 AUTHORITY AND REGULATIONS The programs of the Division of Blood Diseases and Resources, NHLBI, are described in the Catalog of Federal Domestic Assistance No. 93.839. Awards will be made under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grants policies and Federal regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |